CPMP 2005 to Focus on Drug Development via Plant-Made Pharmaceuticals

Share Article

Montreal Conference to Join Leaders in Drug Development and Discovery

Representatives of some of the world’s premier biopharmaceutical companies will gather in Montreal next month to hear 90 speakers on the solutions the plant-made pharmaceutical (PMP) industry offers for drug discovery and development.

Leading corporations including Amgen, Baxter Bioscience, Centocor, Novartis and Wyeth BioPharma will be at the event, the Conference on Plant-Made Pharmaceuticals 2005, to be held at Montreal’s Fairmont Queen Elizabeth Hotel from January 30 to February 2.

More than 25 PMP groups are supporting the conference in a collective, non-for-profit effort. Companies presenting their protein-production platform, products or enabling technologies at the event include Grand Hosts Bayer CropScience (Germany), Dow AgroSciences (USA), Nexgen (Korea), and Syngenta (Switzerland), along with Hosts that include Chlorogen, Fraunhofer, SemBioSys, Medicago and Icon.

Plant-made pharmaceuticals are gaining increasing attention for their potential to aid in the production of therapeutic proteins to treat diseases such as cancer, HIV, heart disease, diabetes, Alzheimer’s disease, arthritis and many more.

Using plants as the vehicle for pharmaceutical production offers a variety of potential advantages, including fast and flexible supply to meet patient needs, lower capital investments than current methods and the ability to produce “difficult” proteins that are otherwise unavailable to the health professionals..

For more information or to register for the conference visit http://www.cpmp2005.org.


Francois Arcand



Share article on social media or email:

View article via:

Pdf Print

Contact Author

Francois Arcand
Visit website